12A Genetic Cure: Gene Therapy Restoring Hearing
For one specific genetic deafness, the most striking recent result in the whole field is not a better electrode - it is children who could not hear, hearing after a single injection into the cochlea. OTOF gene therapy is the first credible biological alternative to an implant, for a narrow but real group.
CThe landmark trials (2023-2025)
From 2023 onward, multiple groups reported AAV-delivered OTOF gene therapy restoring hearing in children with DFNB9 (otoferlin-related deafness): a first-in-human single-arm trial showed recovery in 5 of 6 children. A follow-up trial delivered the therapy to both ears, restoring hearing bilaterally and improving sound localisation, with no serious adverse events reported. Independent programmes converged on the same target: Regeneron's dual-AAV DB-OTO (CHORD trial) and the Akouos AK-OTOF programme, with results in major journals. These are early-phase trials in small numbers of children, but the effect size - profound deafness to useful, often near-normal hearing - is unprecedented for a biological therapy of the ear.[2024][2024][2026]
THow it works, and why OTOF is the ideal first target
Otoferlin is a presynaptic protein at the inner-hair-cell ribbon synapse; without it, hair cells detect sound but cannot release neurotransmitter to the nerve - sound enters but no signal leaves. Crucially, the DFNB9 cochlea is anatomically intact: normal hair cells, normal auditory nerve - only the synaptic transmitter machinery is missing, so simply restoring the protein restores function. An AAV vector carries a working OTOF gene into the inner hair cells (DB-OTO uses two AAVs to fit the large gene and a hair-cell-specific promoter), and the cell makes its own otoferlin. This is why OTOF was the right first target - a presynaptic single-gene defect in an otherwise healthy cochlea is the closest the inner ear offers to a clean 'replace the missing part' problem.[2024][2026][2014]
CWhat it means for cochlear implantation
For a child with confirmed biallelic OTOF mutations, gene therapy raises a genuine alternative to an implant - biological restoration of the native pathway rather than electrical bypass. DFNB9 accounts for only a few per cent of hereditary deafness, so this does not displace implantation broadly - it carves out one molecularly defined subgroup. It reframes the diagnostic work-up: genetic testing now has therapeutic stakes, because identifying OTOF may change the recommended treatment, not just the prognosis. For non-OTOF deafness - the great majority - the cochlear implant remains the standard of care; gene therapy is gene-specific, not a general cure for deafness.[2024][2014]
CThe honest limits
The therapy is gene-specific: it works because OTOF is presynaptic in an intact cochlea, and that logic does not transfer to genes causing hair-cell loss or anatomical malformation. It is early: small cohorts, short-to-medium follow-up, and durability (does one dose last a lifetime?) and re-dosing in the face of anti-AAV immunity are still being established. Long-term safety, the optimal age to treat, and outcomes outside ideal candidates remain open questions appropriate to a first-generation therapy. The accurate, non-hyped framing: a real, repeatable cure for a narrow genetic subset and a landmark proof that biology can restore hearing - not yet a cure for deafness in general.[2024][2024][2026]
What is the most accurate counsel given current evidence?
Why is OTOF (otoferlin) considered the ideal first target for hearing gene therapy?
Which statement about OTOF gene therapy and cochlear implantation is most accurate?
A correct, non-hyped summary of OTOF gene therapy's current status is that it is: